MOTS-c vs 5-Amino-1MQ.

MOTS-c is a 16-amino-acid mitochondrial-derived peptide encoded within the 12S rRNA region of the mitochondrial genome, first described around 2015. It belongs to a small family of "mitochondrial-derived peptides" that appear to act as metabolic signaling molecules. It is an investigational research compound, not an approved drug, and is frequently grouped with longevity peptides where hype tends to outrun the evidence.

5-Amino-1MQ (5-amino-1-methylquinolinium) is a small-molecule, substrate-site inhibitor of the enzyme nicotinamide N-methyltransferase (NNMT). Despite being grouped with "peptides" in the research-chemical marketplace, it is not a peptide at all but a methylquinolinium heterocyclic salt that emerged from academic medicinal-chemistry work at the University of Texas aimed at producing membrane-permeable NNMT inhibitors. It is an investigational research compound, not an approved drug.

In preclinical models MOTS-c is described as a stress-responsive signaling peptide: it has been reported to activate the AMPK energy-sensing pathway and to influence folate and methionine (one-carbon) metabolism, and under metabolic stress it can translocate to the cell nucleus where it is proposed to help regulate adaptive, antioxidant gene expression. These mechanisms are largely characterized in cell and animal systems; how faithfully they translate to a clinical effect in people is not established.

NNMT is a cytosolic enzyme that transfers a methyl group from S-adenosylmethionine (SAM) to nicotinamide, generating 1-methylnicotinamide (1-MNA) and S-adenosylhomocysteine (SAH). Because nicotinamide is the precursor for NAD+ salvage, high NNMT activity in adipose tissue is thought to drain nicotinamide away from NAD+ synthesis and consume SAM. By occupying the nicotinamide substrate site, 5-Amino-1MQ lowers cellular 1-MNA and is proposed to spare nicotinamide for NAD+ regeneration and free up SAM-cycle methylation capacity. The downstream hypothesis (elevated NAD+ activating sirtuins/AMPK to favor energy expenditure over lipid storage) is mechanistically plausible but is largely inferred from cell and rodent work rather than directly demonstrated in humans.

The evidence base is predominantly preclinical. The foundational study (Lee et al., Cell Metabolism, 2015) reported that MOTS-c promoted metabolic homeostasis and reduced obesity and insulin resistance in mice, and later work has linked it to exercise physiology and measured circulating levels in humans as a biomarker. However, there are no controlled human trials demonstrating that administering MOTS-c produces a meaningful clinical benefit. The gap between the animal/mechanistic data and proven human outcomes is large and should not be glossed over.

The core evidence is preclinical. Neelakantan et al. (Biochemical Pharmacology, 2018) reported that methylquinolinium NNMT inhibitors including 5-Amino-1MQ were membrane-permeable, relatively selective, lowered intracellular 1-MNA, and reduced lipogenesis in 3T3-L1 adipocytes; in diet-induced obese mice on a high-fat diet, systemic NNMT-inhibitor treatment significantly reduced body weight, white adipose mass, and adipocyte size and lowered plasma total cholesterol without changing food intake or producing observable adverse effects. Supporting context comes from Ehebauer et al. (Life Sciences, 2020) on glucose-dependent NNMT regulation in adipocytes, and Dimet-Wiley et al. (Scientific Reports, 2022) combining NNMT inhibition with calorie restriction in obese mice. There are no published human clinical trials, and no human pharmacokinetic or efficacy data for 5-Amino-1MQ have been reported. The human-vs-animal gap here is large and should not be glossed over.

Human safety is essentially uncharacterized. There are no published human toxicology, long-term, or drug-interaction data for administered MOTS-c. As an injectable compound sold research-use-only, the purity, identity, and sterility of non-pharmaceutical material are additional unknowns on top of the absent clinical safety package. It should be regarded as an experimental compound of unknown human risk.

Documented safety data are limited to short rodent studies, in which investigators reported no overt adverse effects at the doses tested; this is not a substitute for human safety characterization. There are no published human toxicology, drug-interaction, long-term, or reproductive-safety data. Theoretical concerns include the broad and context-dependent roles of NNMT and NAD+/SAM metabolism across tissues (liver, cancer, vasculature), the unknown consequences of chronically altering one-carbon/methylation flux, and the unverified purity and identity of material sold as a "research chemical." Because human safety is essentially uncharacterized, it should be regarded as an experimental compound of unknown human risk.

MOTS-c is not approved by the FDA (or any major regulator) for any indication and is not a recognized dietary supplement; it is an investigational, research-use-only compound with no registered human therapeutic trials.

5-Amino-1MQ is not approved by the FDA (or any major regulator) for any indication and is not a recognized dietary supplement; it is an investigational/research-use-only compound with no publicly documented IND or registered human clinical trials. It is not, as of this writing, a WADA-listed prohibited substance by name, though its NAD+/metabolic mechanism is the kind of area anti-doping bodies monitor.